基因芯片技术在肺癌研究中的应用

基因芯片技术是一项新的生物学技术。该技术以其迅速及高通量特点 ,而在肺癌及其它恶性肿瘤研究中具有广泛的用途。本文综述了新近用基因芯片技术在肺癌基因表达及基因功能等研究方面的应用。     

基因芯片在肺癌研究中的应用

基因芯片在肺癌研究中用于检测癌组织与正常组织基因表达的差异、肺癌基因表达谱,癌基因产生突变的检测确定,测序分析,癌细胞耐药基因的检测等。     

基因芯片技术在肺癌研究中的应用

基因芯片技术是一项新的生物学技术。该技术以其迅速及高通量特点，而在肺癌及其它恶性肿瘤研究中具有广泛的用途。本文综述了新近用基因芯片技术在肺癌基因表达及基因功能等研究方面的应用。     

基因芯片在肺癌研究中的应用

基因芯片在肺癌研究中用于检测癌组织与正常组织基因表达的差异、肺癌基因表达谱，癌基因产生突变的检测确定，测序分析，癌细胞耐药 基因的检测等。     

基因芯片技术在法医学中的应用进展

基因芯片,又称DNA芯片或DNA微阵列,是生物芯片的一种,是将大量可寻址的基因序列信息,即DNA序列有序地固定在固体介质上而成.……     

基因芯片技术在胰腺癌中的应用进展

基因芯片技术是近几年发展起来的一项生物技术,可同时对大量基因的表达、突变和多态性进行快速、准确的检测。基因芯片技术为研究肿瘤发生、发展中基因功能分析,提供了强有力的工具。胰腺癌在我国的发病率逐年增长,利用基因芯片技术,为胰腺癌的分子病理诊断、临床预后判断及治疗方案的选择提供理论指导。这必将加速对胰腺癌发生、发展机制的了解,为进一步诊断和治疗提供理论基础。     

组织芯片技术及其在肺癌研究中的应用进展

随着人类基因组计划（human genome project，HGP）的完成，人类基因组研究的重心逐渐进入后基因组时代（postgenome Era），即向基因的功能及基因多样性倾斜。基因芯片（gene microarray）、蛋白质芯片（protein microarray）的广泛应用，发现了大量新的功能基因和蛋白质，但对其功能的进一步确定，须回到组织学的水平，与形态学结构联系起来，需要经过组织形态的研究予以确认和支持，在这样的背景下一种新的生物芯片-组织芯片（tissue microarray，TMA）应运而生。TMA又称组织微阵列，是将数十个、数百个乃至上千个小的组织标本按研究需要整齐地排列在某一载体上（通常是载玻片）所形成的微缩组织切片。组织芯片与基因芯片、蛋白质芯片一起构成了生物芯片系列，被誉为医学、生物学领域的一次革命。     

基因芯片技术在疟疾研究中的应用

20世纪80年代末发展起来的基因芯片技术在生命科学众多研究领域中已显示出强大优势。恶性疟原虫和冈比亚按蚊全基因组测序完成后，该技术开始逐步应用于疟原虫、传疟按蚊以及疟疾动物模型的研究。该文概述了基因芯片的基本原理及其在疟疾研究中的应用。     

基因芯片技术及其在疾病研究中的应用

人类基因组计划(human genome project,HGP)的完成,极大地带动了人类疾病相关基因的定位、克隆、结构与功能研究.人类基因组草图基本绘就之后,人类基因组计划也由此加入到功能基因组时代;生命科学的重点也由基因序列研究上升为基因功能研究,基因芯片就是在这个背景下发展起来的一项先进技术.与传统方法相比,它具有快速、高通量、高准确性、低成本等特点,能够满足临床基因检测的要求;且其操作简单、易于标准化、适于推广,显示出广阔的临床应用前景.本文就基因芯片技术的研究进展及其在疾病研究中的应用做一简要综述.     

基因芯片技术在筛选肝癌差异表达基因研究中的应用进展

肝癌是最常见的恶性肿瘤之一,其死亡率居各种恶性肿瘤前列,但是其发生的分子机制仍知之甚少。基因芯片技术自问世以来已广泛用于人类多种肿瘤基因表达谱等方面的研究。在肝癌研究中,它为肝癌相关基因的研究提供了一种全新的方法,为寻找肝癌相关基因、进一步筛选和研究肝癌基因芯片的差异表达基因、寻找和检测与肝癌发生、发展及预后相关的生物分子标记,进而阐明其发病分子机制和进行有效的预防提供了捷径。本文结合基因芯片技术在筛选肝癌差异表达基因研究中的应用作一综述。     

Gene expression profile differences in gastric cancer, pericancerous epithelium and normal gastric mucosa by gene chip

AIM: To study the difference of gene expression in gastric cancer (T), pericancerous epithelium (P) and normal tissue of gastric mucosa (C), and to screen an associated novel gene in early gastric carcinogenesis by oligonucleotide microarray. METHODS: U133A (Affymetrix, Santa Clara, CA) gene chip was used to detect the gene expression profile difference in T, P and C, respectively. Bioinformatics was used to analyze the detected results. RESULTS: When gastric cancer was compared with normal gastric mucosa, 766 genes were found, with a difference of more than four times in expression levels. Of the 766 genes, 530 were up-regulated (Signal Log Ratio (SLR) >2), and 236 were down-regulated (SLR<-2). When pericancerous epithelium was compared with normal gastric mucosa, 64 genes were found, with a difference of more than four times in expression levels. Of the 64 genes, 50 were up-regulated (SLR>2), and 14 were down-regulated (SLR<-2). Compared with normal gastric mucosa, a total of 143 genes with a difference in expression levels (more than four times, either in cancer or in pericancerous epithelium) were found in gastric cancer (T) and pericancerous epithelium (P). Of the 143 genes, 108 were up-regulated (SLR>2), and 35 were down-regulated (SLR<-2). CONCLUSION: To apply a gene chip could find 143 genes associated with the genes of gastric cancer in pericancerous epithelium, although there were no pathological changes in the tissue slices. More interesting, six genes of pericancerous epithelium were up-regulated in comparison with genes of gastric cancer and three genes were down-regulated in comparison with genes of gastric cancer. It is suggested that these genes may be related to the carcinogenesis and development of early gastric cancer.     

Gene expression profile differences in gastric cancer, pencancerous epithelium and normal gastric mucosa by gene chip

AIM: To study the difference of gene expression in gastric cancer (T), pericancerous epithelium (P) and normal tissue of gastric mucosa (C), and to screen an associated novel gene in early gastric carcinogenesis by oligonudeotide microarray. METHODS: U133A (Affymetrix, Santa Clara, CA) gene chip was used to detect the gene expression profile difference in T, P and C, respectively. Bioinformatics was used to analyze the detected results. RESULTS: When gastric cancer was compared with normal gastric mucosa, 766 genes were found, with a difference of more than four times in expression levels. Of the 766 genes, 530 were up-regulated (Signal Log Ratio [SLR]>2), and 236 were down-regulated (SLR<-2). When pericancerous epithelium was compared with normal gastric mucosa, 64 genes were found, with a difference of more than four times in expression levels. Of the 64 genes, 50 were up-regulated (SLR>2), and 14 were down-regulated (SLR<-2). Compared with normal gastric mucosa, a total of 143 genes with a difference in expression levels (more than four times, either in cancer or in pericancerous epithelium) were found in gastric cancer (T) and pericancerous epithelium (P). Of the 143 genes, 108 were up-regulated (SLR>2), and 35 were down-regulated (SLR<-2). CONCLUSION: To apply a gene chip could find 143 genes associated with the genes of gastric cancer in pericancerous epithelium, although there were no pathological changes in the tissue slices. More interesting, six genes of pericancerous epithelium were up-regulated in comparison with genes of gastric cancer and three genes were down-regulated in comparison with genes of gastric cancer. It is suggested that these genes may be related to the carcinogenesis and development of early gastric cancer.     

RNA干扰在肺癌基因治疗中的应用进展

RNA干扰是近几年在基因表达调控领域的重大发现,是一种经济、快捷、高效的抑制基因表达的技术手段.目前在全球.肺癌发病率呈逐年上升趋势,近10余年来已成为癌症死亡原因之首.肺癌的治疗方法中,靶向基因治疗成为研究热点.RNA干扰作为基因治疗的强大工具,可通过有效沉默原癌基因、细胞凋亡相关基因、细胞周期相关基因、生长因子以及耐药基因等,达到抑制肺癌细胞生长、诱导肺癌细胞凋亡、增强其对化疗或放疗的敏感性的目的 .RNA干扰已经广泛应用于肺癌的基因治疗,发挥其明显的抗癌作用.     

肺癌患者p16基因检测的研究进展

细胞周期与细胞癌变密切相关，抑癌基因p16参与细胞周期调控,p16的改变可导致细胞的失控性生长，所以p16基因可成为肿瘤选择作用的治疗靶点。p16基因检测对肺癌的发病机制研究、早期诊断、预后评估和分子靶向治疗有一定帮助。     

肺癌患者外周血单个核细胞hTERT基因表达在诊断中的价值

目的探讨外周血单个核细胞(PBMCs)的人端粒酶反转录酶(hTERT)基因的表达水平对于肺癌的诊断意义。方法采用RT-PCR定量检测中国医科大学第二临床学院干诊科2002-03~2005-0230例肺癌住院患者及15名正常人外周血单个核细胞的hTERT的基因表达水平。结果肺癌患者和正常对照组的hTERTmRNA的吸光度值分别为0.906±0.112,0.407±0.104。两者比较差异有显著性(P<0.01)。结论定量测定PBMCs的hTERTmRNA的表达水平是诊断肺癌患者的有效方法。     

肺癌患者白介素1受体拮抗剂基因多态性的研究

目的 对肺癌患者和健康人的白介素1受体拮抗剂基因(interleukin-1 receptor antagonist gene,IL-1RN)多态性进行研究,探讨IL-1RN与肺癌易感性的关系.方法 采用聚合酶链式反应技术对148例肺癌患者和150名健康对照者的IL-1RN基因多态性进行分析.结果 Ⅱ类等位基因(IL-...     

长链非编码RNA与肺癌相关性的研究进展

肺癌是目前全世界发病率和病死率最高的恶性肿瘤.长链非编码RNA(lncRNA)是一类转录本长度超过200 nt的RNA,不能编码任何蛋白质.当前研究提示lncRNA在表观遗传学调控、转录水平调控及转录后调控等层面上发挥重要的调控作用.如今lncRNA与肺癌之间的关联成为一个新的研究热点.研究发现MALAT1、H19、lincRNA p21、lncRNA-SCAL1、BC200与肺癌的发生、发展有密切关系.本文对lncRNA在肺癌中的研究进展进行综述,为肺癌的早期临床诊断、治疗及预后提供参考.     

Molecular biology of lung cancer: clinical implications

Lung cancer is a heterogeneous disease clinically, biologically, histologically, and molecularly. Understanding the molecular causes of this heterogeneity, which might reflect changes occurring in different classes of epithelial cells or different molecular changes occurring in the same target lung epithelial cells, is the focus of current research. Identifying the genes and pathways involved, determining how they relate to the biological behavior of lung cancer, and their utility as diagnostic and therapeutic targets are important basic and translational research issues. This article reviews current information on the key molecular steps in lung cancer pathogenesis, their timing, and clinical implications.